Voximetry
Voximetry
Voximetry
PERSONALIZED DOSIMETRY FOR RADIOPHARMACEUTICAL THERAPY
Voximetry
Voximetry
Torch™ has not yet been submitted to FDA for review of its Indications for Use and is therefore NOT suitable for clinical use.
About Us
From Generalized to Personalized Medicine
Voximetry, founded in Madison, WI in 2016, is an early stage healthcare technology company that specializes in commercializing improvements related to nuclear medicine dosimetry. Voximetry’s patient-specific approach can accurately predict efficacy and adverse effects of radiopharmaceutical therapy, thereby improving patient outcomes. Voximetry leverages intellectual property developed at the University of Wisconsin - Madison, which has a rich history of fostering successful biotechnology companies.
COMPANY NEWS
VOXIMETRY AWARDED $100,000 SBIR ADVANCE MATCH GRANT
3/8/2021 - Read More>>
VOXIMETRY NAMES SUE WALLACE AS CEO
1/19/2021 - Voximetry continues its momentum with hiring of Chief Executive Officer Dr. Sue Wallace. Read More>>
IROC TO USE TORCH™ IN UPCOMING NCTN CLINICAL TRIALS
11/9/2020 - Voximetry and the Imaging and Radiation Oncology Core (IROC) have reached agreement to evaluate the role of dosimetry in alpha- and beta-emitting Radiopharmaceutical Therapy (RPT) clinical trials. Read more>>
STRATEGIC PRODUCT DEVELOPMENT INVESTMENT
11/3/2020 - Sankara Hari Gopalakrishnan has joined Voximetry as a Senior Software Engineer for Image Processing and Optimization Algorithms. He will be advancing Voximetry's Torch™ software in the areas of deformable registration, contour propagation, and optimization. Read more>>
VOXIMETRY RECEIVES $1.8M SBIR PHASE II GRANT
10/15/2020 - Voximetry has been awarded a Phase II Small Business Innovation Research (SBIR) grant valued at $1.8 million from the National Cancer Institute (NCI). This award will assist Voximetry in commercializing its Torch™ software for RPT treatment planning. Read more>>
VOXIMETRY TO PROVIDE DOSIMETRY FOR PHASE I RPT CLINICAL TRIAL
9/21/2019 - Voximetry will be partnering with Viewpoint Molecular Imaging to provide dosimetry on clinical trials of new RPT drugs. Phase I trials of the VMT01 companion diagnostic agent are expected to commence at Mayo Clinic early in 2020.